Vital Care Compounder LLC (Pharmacy Plus, Inc.), Hattiesburg, MS
Is Vital Care Compounder LLC (Pharmacy Plus, Inc.) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Vital Care Compounder LLC (Pharmacy Plus, Inc.) hold a Mississippi pharmacy license?
State board of pharmacy records for Mississippi are not checked: the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search.
Has Vital Care Compounder LLC (Pharmacy Plus, Inc.) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jun 6, 2023) for Vital Care Compounder LLC (Pharmacy Plus, Inc.). State board of pharmacy records for Mississippi are not checked: the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Pharmacy Plus, Inc.; Vital Care Compounder LLC
- Location
- Hattiesburg, MS
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Jun 6, 2023
- FDA Data Dashboard inspections
- No matching site found
- Form 483 text on this page
- 1 Form 483, 10 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Pharmacy Plus, Inc. (dba Vital Care Compounder LLC), a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Jun 6, 2023 | Warning letter | Warning Letter (06/06/2023) | FDA copy (archived) |
| Oct 13, 2022 | Form 483 | 483 Issued 10/13/2022 | FDA copy (archived) |
| May 16, 2019 | Form 483 | 483 Issued 05/16/2019 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
The dashboard does list Vital Care Compounder, Inc, Hattiesburg, MS (FEI 3010241801): same name and state, different city, so not treated as this site.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 10 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Oct 3, 2022 to Oct 13, 2022: 10 observations
- Firm on the cover
- Pharmacy Plus, Inc. dba Vital Care Compounder, 115 S 40th Ave, Hattiesburg, MS 39402-6600
- FEI number
- 3010241801
- Establishment type on the cover
- Producer of St erile and Non-Sterile Drug Products
- FDA district office on the cover
- 404 BNA Dr., Bldg. 200, Ste. 500 Nashville, TN 37217-2597
- Matched to this page by
- firm name, city and state on the cover; linked from actions page
- FDA document
- Read the full 483 (Internet Archive copy FDA links)
Observation 1
You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in the ISO 5 classified aseptic processing area during aseptic production.
Specifically, on 3/29/22 your firm's certification company detected an out-of-specification, <Redacted B4>, for active air (fungus organisms identified: Cladosporium spp, Eptcoccum ingram, Pencillin commune, etc.) within your fnm's ISO-5 <Redacted B4> laminar airflow hood <Redacted B4>). Penicillum commune, From 8/4/21 (previous certificatiion that detected no growth, through 3/29/22, your firm produced and dispensed approximately <Redacted B4> lots. The six (6) lot numbers listed below are still on the market within expiration:
• Cyclosporin Ophthalmic 2% Oil <Redacted B4>, 3,000mL, lot #58 114, BUD:11/25/22
• Medroxyprogesterone Acetate 300mg/mL Suspension, l,000mL, lot #55786, BUD:12/31/22
• Tacrolimus Ophthalmic 0.02% Suspension <Redacted B4>, 2,400mL, lot #55228, BUD:12/17/22
• Papaverine/Phentolamine Injection 150mg/5mg Vial Solution, 500mL, lot #55092, BUD:10/22/22
• Methylcobalamin PF lmL Injection Solution 5,000MCG/mL, 500mL, lot#57997, BUD:2/25/23 ...
Observation 2
The cycle parameters, <Redacted B4> used for <Redacted B4> sterilization of product intended to be sterile were not lethal to heat-resistant microorganisms.
Specifically, biological indicators (BIs) were not used to verify the adequacy of your firm's sterilization cycles by <Redacted B4> our suspension drug products (e.g., Triamcinolone) and by <Redacted B4> for your <Redacted B4> drug products (e.g., Cyclosporin).
Observation 3
The final containers/closures used for drug product intended to be sterile were not sterilized an <Redacted B4> i - · Specifically, your firm conducted a <Redacted B4> study on 9/30/22 for the <Redacted B4>. These vials were not used in production but were intended to demonstrate the effectiveness of the cycle time which is used to <Redacted B4> sterilize empty <Redacted B4> vials. On 10/4/22, day 5 of <Redacted B4> of <Redacted B4> the four biological indicators used failed. Your firm's cycle time is potentially insufficient in achieving sterilization of empty <Redacted B4> vials.
In addition, your firm assigns a 6-month BUD after sterilization <Redacted B4> for un-used (left over from a batch) purchased sterile vial <Redacted B4>. Your firm has no assurance that these critical product contact surfaces maintain their sterility for this duration.
Observation 4
The ISO 5 classified aseptic processing areas had difficult to clean, particle-generating and visibly dirty equipment or surface.
Specifically, on 10/3/22, the following deficiencies were observed in your firm's ISO-5 <Redacted B4> pertaining to inadequate cleaning and sanitization and potential paiiicle generating supplies.
a. Rust-like stains were observed on the stainless-steel within your firm's <Redacted B4>.
b. The sleeves within the <Redacted B4> contained <Redacted B4> nuts and gaskets with grooves which are difficult to clean as they are not disassembled. In addition, according to your firm's operator, the interior portion of the sleeves within your ISO-5 <Redacted B4> is not cleaned and sanitized and <Redacted B4> places <Redacted B4> hands inside of them to access the unit.
C. A household non-sterile trash bag was observed to be secured with an elastic rubber band on the right side of the working surface within your <Redacted B4> which cannot be adequately cleaned and sanitized and can introduce Inicrobial and particulate contamination. The trash bag contained used supplies from the last lot of Mitomycin Injection, 0.375mg/mL, lot #66536 produced on 9/27/22.
Observation 5
Disinfecting agents and cleaning pads and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.
Specifically, on 10/4/22, prior to aseptic operations of finished drug product, DMSO with Lidocaine 50%/0.5%, lot #66829, Use by: 10/5/22 (QTY: 1 vial) (Bladder Irrigation) your firm's operator was observed cleaning the ISO 5 laminar airflow hood with a non-sterile cleaning pad. In addition, on 10/4/22, during the <Redacted B4> cleaning, your firm's facilities manager was observed cleaning the interior surfaces of the ISO-5 hoods with non-sterile wipes.
observed cleaning the ISO 5 laminar airflow hood with a non-sterile cleaning pad. In addition, on 10/4/22, during the (b (4 1 cleaning, your fnm 's facilities manager was observed cleaning the interior surfaces of the ISO-5 hoods with non-sterile wipes.
Observation 6
Personnel used a non-sterile tool on and manually contacted the inner surface of the container or closure.
Specifically, on 10/4/22, during aseptic operations of finished drug product, DMSO with Lidocaine 50%/0.5%, lot #66829, Use by: 10/5/22 (QTY: 1 vial) (Bladder Irrigation) your firm's operator was observed <Redacted B4> the finished product vial with the <Redacted B4> bag. Your operator stated for larger batch sizes she uses her <Redacted B4> hand.
Observation 7
Personnel did not disinfect and change gloves frequently enough to prevent contamination.
Specifically, on 10/4/22, during aseptic operations of finished drug product, DMSO with Lidocaine 50%/0.5%, lot #66829, Use by: 10/5/22 (QTY: 1 Vial) (Bladder Irrigation) your firm's operator was observed spraying <Redacted B4> hands with <Redacted B4> within the ISO-7 Cleanroom then wiped <Redacted B4> hands with a wipe exposed to lower quality air that was left open on a caii within the ISO 7 Cleanroom. The operator then proceeded to produce the drug product aseptically within the ISO 5 <Redacted B4> laminar airflow hood without first disinfecting <Redacted B4> gloves.
Observation 8
You produced hazardous drugs without providing adequate segregation, cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.
Specifically, according to your firm's Director of Operations, your firm conducts weighing of these hazardous bulk drug substances (mitomycin, cyclosporin and testosterone) within your non-sterile <Redacted B4> hood which is also used for the weighing/mixing of non-hazardous bulk drug substances without cleaning of the work surfaces and equipment with a deactivating agent (e.g., oxidizing agent).
Observation 9
Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.
Your firm's, "High Risk Media Fill <Redacted B4>, dated 3/4/22, 3/16/22, 8/22/22 and 8/30/22 are inadequate as they fail to incorporate the largest batch sizes for each operator that would simulate various aseptic production operations (e.g., <Redacted B4> as well as include difterent container closure systems <Redacted B4> that potentially challenge your aseptic operations. in addition, your firm <Redacted B4> sterilized a portion of the media fill vials which fails to evaluate the operator's aseptic technique. Lastly, your firm failed to <Redacted B4> all media fill vials.
Observation 10
ISO-5 classified areas were not adequately certified under dynamic conditions.
Specifically unidirectional airflow was not verified under operational conditions within your firm's ISO-5 <Redacted B4> laminar airflow <Redacted B4> (designated for <Redacted B4>). During the smoke study video labeled August 2022, the air is observed moving <Redacted B4> The smoke study fails to incorporate all aseptic operations, simulated manipulations, and supplies (e.g., sterile IV bags <Redacted B4> or larger, transfer tubing, etc.), used in routine production that can potentially disrupt unidirectional airflow within the ISO-5 unit.
Linked 483s whose text is not shown
- May 16, 2019: FDA document 128811: the FEI number and firm name on its cover do not match this page by the rule.
State board of pharmacy records
State board of pharmacy records for Mississippi are not checked: the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search.
GLP-1 warning letters
FDA’s posted warning letters that name a GLP-1 drug include 0 letters to Pharmacy Plus, Inc. dba Vital Care Compounder. See the Pharmacy Plus, Inc. dba Vital Care Compounder record page for those letters and any recalls.
No FDA warning letters in this index.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- FDA warning letters (fda.gov full-text search)
Records last pulled Nov 15, 2026. Every entry links to the original public record.